Biotech Blues continuum

Bangalore-based Biocon said on June 29 that it would tie-up with USA's Mylan to supply biosimilars. Mylan will have "exclusive commercialisation rights in the US, Canada, Japan, Australia, New Zealand and in the European Union and countries of the European Free Trade Association" says a report in Business Line.  This bears out what I said …

Advertisement

Biotech blues

It is more or less certain that Indian companies cannot repeat their relatively early success in chemical generics with biosimilars on the global stage. Indian biosimilars will sell - make no mistake. But it will likely be a whole bunch of large pharma and biotech companies like Merck, and Biogen selling them under their label. Why do …

Doctor’s prescription

I happened to meet Dr Ajai Kumar of Bangalore-based HealthCare Global (HCG) in Mumbai for a quick discussion on what his company has been upto. The radiation and medical oncologist is busy expanding a cancer hospitals network which currently has 16 centres specialising in cancer care in the country. He was in Mumbai to raise …

Advantage Advinus

This week, I visited the new drug discovery laboratories of Advinus Therapeutics in Hinjewadi, Pune. For those of you who don't already know, Advinus is backed by the Tata group and operates from two sites.  The one in Bangalore houses drug development while in Pune it has about a hundred scientists engaged in the quest …

Herbal remedies

The Washington Post reports that the US government spent an eye-popping $2.5bn over the last decade on testing alternative therapies and medicines.  The results were not encouraging though critics suggest that the testing process was flawed. Be that as it may, this brought me to wonder - as I have for a while - why Indian companies and the …